UY33662A - Combinaciones que comprenden inhibidores de dhodh e inhibidores de cox - Google Patents

Combinaciones que comprenden inhibidores de dhodh e inhibidores de cox

Info

Publication number
UY33662A
UY33662A UY0001033662A UY33662A UY33662A UY 33662 A UY33662 A UY 33662A UY 0001033662 A UY0001033662 A UY 0001033662A UY 33662 A UY33662 A UY 33662A UY 33662 A UY33662 A UY 33662A
Authority
UY
Uruguay
Prior art keywords
inhibitors
combinations
dhodh
cox
cox inhibitors
Prior art date
Application number
UY0001033662A
Other languages
English (en)
Inventor
Godessart Marina Nuria
Balague Pelaez Cristina
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of UY33662A publication Critical patent/UY33662A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen combinaciones que comprenden (a) inhibidores de DHODH y (b) inhibidores de COX y su uso en el tratamiento de enfermedades o trastornos de la piel.
UY0001033662A 2010-10-22 2011-10-11 Combinaciones que comprenden inhibidores de dhodh e inhibidores de cox UY33662A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382276A EP2444086A1 (en) 2010-10-22 2010-10-22 Combinations comprising DHODH inhibitors and COX inhibitors

Publications (1)

Publication Number Publication Date
UY33662A true UY33662A (es) 2012-05-31

Family

ID=43630020

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033662A UY33662A (es) 2010-10-22 2011-10-11 Combinaciones que comprenden inhibidores de dhodh e inhibidores de cox

Country Status (5)

Country Link
EP (1) EP2444086A1 (es)
AR (1) AR083491A1 (es)
TW (1) TW201216966A (es)
UY (1) UY33662A (es)
WO (1) WO2012052180A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103520137B (zh) * 2012-07-03 2016-02-03 沈阳药科大学 治疗类风湿性关节炎的复方特立氟胺透皮贴剂及制备方法
CN110251498A (zh) * 2018-03-12 2019-09-20 厦门大学 一类调节法尼醇受体活性的化合物及其用途
CA3094324A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
CA3118698A1 (en) * 2018-11-05 2020-05-14 Apramitha Innovations Private Limited Teriflunomide topical pharmaceutical compositions
US12076315B2 (en) 2020-03-20 2024-09-03 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
WO2001003688A2 (en) * 1999-07-09 2001-01-18 Pharmacia Corporation Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
WO2005004806A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Combination therapy for treating chronic inflammatory diseases
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
KR20090064865A (ko) * 2007-12-17 2009-06-22 건국대학교 산학협력단 5-데옥시캠페롤을 포함하는 피부 염증, 피부질환과 피부암예방 및 치료제
EP2210615A1 (en) * 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors

Also Published As

Publication number Publication date
TW201216966A (en) 2012-05-01
WO2012052180A1 (en) 2012-04-26
EP2444086A1 (en) 2012-04-25
AR083491A1 (es) 2013-02-27

Similar Documents

Publication Publication Date Title
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
SMT201600398B (it) Inibitori di proteina chinasi (varianti), uso di questi nel trattamento di malattie oncologiche e composizione farmaceutica basata su questi
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
EA201500934A1 (ru) Кардио- и нефропротективная противодиабетическая терапия
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2014002342A1 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma.
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CR20130134A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
BRPI0906167A2 (pt) uso de inibidor de serina protease no tratamento de doenças de pele.
BR112015022854A2 (pt) pró-farmacos de fumaratos e uso do mesmo no tratamento de várias doenças
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
ECSP13012402A (es) Inmunoglobulinas con dominio variable dual y su uso
AR075442A1 (es) Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CR20120508A (es) PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
UY33662A (es) Combinaciones que comprenden inhibidores de dhodh e inhibidores de cox
CO6700840A2 (es) Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia